Record revenue masked by weak QoQ growth, domestic slowdown emerges

₹74.7 Cr confirms record. But QoQ growth only 1.0%, signaling sequential deceleration.

EBITDA 19.2% confirmed. PAT margin delivered at 13.4%, not 13.8% stated on call—40 bps overstate.

Consolidated lab segment 23.5% includes international (37.4%). Domestic lab ex-scanners only 12% YoY—weak. Claims acceleration from Q2 unproven.

37.4% confirmed. CFO disclosed ~10–12% USD tailwind, implying 25–27% organic growth—strong but currency-aided, not purely execution-driven.

Q1 delivered 13.9% YoY revenue growth, already below 15% lower bound on guidance. Margins within range at 19.2% EBITDA. Guidance execution risk evident.

Prior call (FY26) implied 16% growth trajectory. Q1 domestic lab (ex-scanners) at only 12%. Reframed as 'maturation phase' but below expectations.

Gestation period now explicitly 6 months to 1.5 years (vs. implied faster payoff). Management candid that J-curve timing uncertain.

37.4% growth includes ~10–12% USD tailwind. Organic ~25–27%. Strong but currency-dependent; headwind risk if USD softens.

Palghar acquisition (letter of intent); planned transition from ₹2 Cr/year rent to owned 3x capacity facility. De-risking long-term cost structure.

Trust (36-year history), global quality standards, material/process consistency, ongoing innovation, and only branded player in crown category. Cross-sell via existing dentist relationships.

Scanners are trading margins (15–20%). Exclude scanners, underlying margins stable/rising. Lab and aligner margins improving despite mix. Minor fluctuations acceptable for long-term digital dentistry play.

Aligners ~70% (reasonable headroom for growth). Lab ~90–95% (custom, less automated). Scaling aligner automation and lab digitization underway.

Domestic 75–80%, international majority digital. Combining lab and aligner business. Ongoing scanner rollout targeting higher penetration.

Scanner adoption at 7–8% penetration; significant headroom. Industry adopting scanners. Demand good now; timing of J-curve inflection uncertain. Monitoring technology roadmap continuously.

Current rent ₹2 Cr/year for two facilities. Palghar enables 3x scale, owned property eliminates rent escalation (future ₹5–6 Cr). Phased digital transition minimizes disruption; Boisar 2020 COVID transition cited as success precedent.

Hitting maturity in scanner deployment phase. Satellite labs added, closer customer proximity. Expecting momentum upwards Q2–Q4 as scanner base matures and conversions accelerate.

CEO 11+ years dental experience; certain initiatives could shape well in couple quarters. (Deferred specifics to 1-on-1.) AI: beta AI crown models cost higher now; cost will normalize as scale increases. Margin impact temporary.

USD moved INR85→INR95 (~12% tailwind). Reported 37.4%, implying ~25–27% organic. DSO and retail growth also strong. Currency benefit may arbitrage in future quarters; underlying organic growth very strong.

iScope home monitoring technology, education, training, dental events, AI initiatives. Launching 2–3 more offerings Q2–Q4. Growth momentum sustainable; cost headwinds this year but normalizing next year.

Gestation 6 months to 1.5 years in some cases. Current 12% domestic lab growth expected to accelerate Q2–Q4 as scanner base matures and conversions follow.

Scanners being deployed; now entering maturity/growth phase. Satellite labs added, closer to customers. Expect acceleration from Q2 onward. Multiple initiatives layered.

Competition exists and will continue. Counter-strategy: innovate, cross-sell existing customer base (36-year dental relationships), leverage experience. Confidence in counter-strategies.

Constantly exploring. Quarterly pilot-phase country additions; graduation to scaling and business phases. Organic, phased international rollout.

B2C absolutely not. Only D2B via dentists (all types: ortho, general, perio, endo). Field orthodontists support dentist customers. Globally, general dentists driving aligner growth; educating and building confidence.

800–1,000 scanners planned for FY27. Monitoring demand and adoption continuously. Still on track despite macro uncertainty.

Yes, excluding scanner mix volatility. Scanner sales (20% margin, 80% cost) may cause minor dips. Aligners and lab margins rising. Underlying momentum positive.

Aspirational guidance: 15–20% revenue growth, 18–20% EBITDA margin (prior targets, achievable with ESOP normalization and operational leverage). Reached these in past; confident in range.

Market valuation outside our control. Our focus: performance (controllables). Q1 strong, margins up, revenue record. Dental awareness rising globally. Company bullish, buying back at ₹200. Excited about 5–10 year outlook.

Brand ambassadors (Kareena Kapoor), in-clinic branding, social media advertising, patient education (ask dentist for brand). Long-term play. Branding will be key differentiator in 3–5 years. First-mover in branded crowns.

Goal to outgrow industry as market leader. Heavy investment: Kareena branding, education, training, social media. 3–5 year horizon to build very strong aligner brand domestically.

Holistic company view. Dentist is customer; revenue from lab, aligner, or other. Mix evolves with customer demand. If aligner explodes (as globally), dentist mix changes naturally. Not choosing between segments.

Reiteration of prior long-standing target. Q1 at 13.9% already below 15% lower bound—execution risk evident on near-term.

Q1 at 19.2% comfortably within range. Scanner mix and AI automation are variables. Lab/aligner margins improving; underlying operational leverage positive.

Facility transition to owned property (3x scale, rent savings ₹2→5–6 Cr). Phased approach, no major Q1 P&L impact yet. Execution risk on timeline.

Domestic lab ex-scanners at 12% YoY vs. international 37.4%, aligner 28.6%. Management reframes as 'maturation' but segment clearly lagging.

Management disclosed scanner conversion gestation 6 months to 1.5 years. J-curve timing and 800–1,000 FY27 deployment realization at risk if adoption slows.

Aligner segment growing 28.6% but in fragmented/competitive space. Brand building (Kareena ambassador) early-stage; differentiation via education and innovation requires sustained execution.

Palghar facility still at LOI stage. Transition from two rented facilities (₹2 Cr/year) to owned property carries real estate acquisition, construction, and logistics risks.

International growth 37.4% includes ~10–12% USD tailwind (INR85→INR95). If USD weakens, reported growth will decelerate despite stable organic growth.